F064 Neurobehavioural and psychiatric symptom prevalence within stage 2 of the integrated staging system for HD

<h3>Background</h3> Huntington’s Disease (HD) is a neurodegenerative disease that follows an autosomal dominant inheritance pattern. The motor symptoms associated with HD are well characterised and characterological on manifestation, however, there are also significant behavioural and psychiatric symptom phenotypes. The HD biological classification and Integrated Staging System have introduced helpful criteria to consider progression within HD. In brief, the stages use the following criteria: Stage 0: positive genetic expansion; Stage 1: identifiable biomarkers of degeneration in the brain; Stage 2 is classified as measurable motor or cognitive symptoms using verified measures, and; Stage 3: relates to functional changes which are considered mild, moderate, or severe in nature. While the biological staging system is undoubtedly useful, this research considered the extent to which people experience psychiatric and behavioural change secondary to HD within Stage 2, at the time of cognitive or motor features. <h3>Aims</h3> This study aims to consider the prevalence and profile of psychiatric and behavioural symptoms within Stage 2 of HD. The objective is to use the Enroll-HD data to inform a person-centred approach to clinical care within Stage 2 biological classifications, inclusive of neuropsychiatric and neuropsychological considerations for treatment. <h3>Methods</h3> Secondary data was derived through the Enroll-HD PDS-6 database, to identify individuals within Stage 2 i.e., gene-positive, with objectively reduced motor or cognitive outcomes as outlined by Tabrizi et al. Further, all available variables relating to mood, behaviour, or psychiatric change were considered as outcome measures i.e., PBA-s subscales, HADS. <h3>Results/Outcome</h3> Prevalence assessment and profiling is ongoing, and the aim of this study will be to determine the type, frequency, and severity of behaviour and psychiatric experiences associated with Stage 2 with the HD-ISS, alongside the established biological classification criteria of movement and cognitive change.